Novo Nordisk to increase manufacturing capacity of weight-loss drugs

"As we look to launch future products, obviously we will take into consideration more of a 'pull' than a 'push' commercial strategy. And that links into how we scale capacity for that," Chief Executive Lars Fruergaard Jorgensen told journalists in a call on nine-month results. "We see this pull nature in the market for anti-obesity medicine, which is fantastic because we have the broadest portfolio in the industry to do that," he added.

Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year. "As we look to launch future products, obviously we will take into consideration more of a 'pull' than a 'push' commercial strategy. And that links into how we scale capacity for that," Chief Executive Lars Fruergaard Jorgensen told journalists in a call on nine-month results.

"We see this pull nature in the market for anti-obesity medicine, which is fantastic because we have the broadest portfolio in the industry to do that," he added. The company is in a drawn-out production revamp after a contractor filling Wegovy injection pens ran into problems late last year.

Also Read: European shares open higher ahead of Fed decision, Novo Nordisk shines